Morgan Stanley maintains DexCom (NASDAQ:DXCM) with a Equal-Weight and lowers the price target from $576 to $570.
Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $570
Morgan Stanley maintains DexCom (NASDAQ:DXCM) with a Equal-Weight and lowers the price target from $576 to $570.
Related Posts
Keybanc Maintains Overweight on Lennar, Raises Price Target to $100
Keybanc analyst Kenneth Zener maintains Lennar (NYSE:LEN) with a Overweight and raises the price target from $89 to $100.
Immunome To Present Preclinical Data On Anti IL-38 Antibody Program At The American Association For Cancer Research NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it will be making an oral poster
Bitcoin Traders Fooled On ‘Buy The Dip’ Calls: This Signal Shows Best Time To Enter
Data shows that a large number of cryptocurrency traders have been fooled by calls to “buy the dip.”
What Happened: Blockchain analytics platform Santiment has established a reliable trend of the mainstream crowd being incorrect on calls to buy the dip.